- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06132113
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
DAREON™-7: A Phase I, Open-label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-line Treatment of Patients With Neuroendocrine Carcinomas (NEC)
This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3.
The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has 2 parts. Part A of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. The purpose of Part B is to find out how well people can tolerate BI 764532 in combination with different chemotherapies. Researchers also want to find out whether BI 764532 in combination with chemotherapy helps people with NEC.
Participants get different doses of BI 764532 as an infusion into a vein. In addition, they get platinum-based chemotherapy as infusions into a vein. Participants can continue treatment up to 3 years if they benefit from treatment and can tolerate it.
Participants visit their doctors regularly. During these visits, the doctors collect information about participants' health and take note of any unwanted effects. Doctors also regularly check the size of the tumour.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Boehringer Ingelheim
- Phone Number: 1-800-243-0127
- Email: clintriage.rdg@boehringer-ingelheim.com
Study Locations
-
-
-
Tübingen, Germany, 72076
- Recruiting
- Universitätsklinikum Tübingen
-
Contact:
- Boehringer Ingelheim
- Phone Number: 08007234742
- Email: deutschland@bitrialsupport.com
-
-
-
-
-
Aichi, Nagoya, Japan, 464-8681
- Recruiting
- Aichi Cancer Center Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
Chiba, Kashiwa, Japan, 277-8577
- Recruiting
- National Cancer Center Hospital East
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
Osaka, Osaka, Japan, 541-8567
- Recruiting
- Osaka International Cancer Institute
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
Tokyo, Chuo-ku, Japan, 104-0045
- Recruiting
- National Cancer Center Hospital
-
Contact:
- Boehringer Ingelheim
- Phone Number: 0120201230
- Email: nippon@bitrialsupport.com
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Vall d'Hebron
-
Contact:
- Boehringer Ingelheim
- Phone Number: 900876092
- Email: espana@bitrialsupport.com
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Contact:
- Boehringer Ingelheim
- Phone Number: 900876092
- Email: espana@bitrialsupport.com
-
Madrid, Spain, 28046
- Recruiting
- Hospital La Paz
-
Contact:
- Boehringer Ingelheim
- Phone Number: 900876092
- Email: espana@bitrialsupport.com
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the informed consent form (ICF)
- Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses
Patients diagnosed with locally advanced or metastatic NEC of following subtypes:
- extrapulmonary neuroendocrine carcinomas (epNEC)
- pulmonary large cell NEC (LCNEC)
- neuroendocrine carcinomas (NEC) of unknown primary site
- Patients with tumours with mixed histologies for any above type are eligible only if neuroendocrine carcinoma/small tumour cells component is predominant and represent at least 50% of the overall tumour tissue
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Minimum life expectancy of 12 weeks
- At least one measurable lesion as defined per RECIST 1.1 within 35 days prior to the first dose of BI 764532
Patients with a history of asymptomatic Central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria:
- No radiotherapy (including whole brain radiation therapy, stereotactic radiotherapy or radiosurgery) within 7 days
- Are neurologically stable without the need for steroids or anti-convulsants for at least 7 days before first dose of BI 764532 as per local site assessment Further inclusion criteria apply.
Exclusion Criteria:
- Previous treatment in this trial
- Current enrolment in another investigational device or drug trial, or <30 days since ending another investigational device or drug trial(s)
- Patients with diagnosis of Merkel cell carcinoma or medullary thyroid carcinoma or Grade 3 neuroendocrine tumour
- Presence of leptomeningeal carcinomatosis
- Previous treatment with DLL3-targeting T cell engagers and cell therapies
- Patients who have been treated with extensive field radiotherapy including whole brain irradiation within 1 week prior to first administration of BI 764532
- Major surgery (major according to the investigator's assessment) within 28 days prior to first administration of BI 764532 or planned during treatment period, e.g. hip replacement
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to Screening (other than the target indication), except for appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix Further exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: BI 764532 low dose + carboplatin + etoposide
|
BI 764532
Standard of care
Standard of care
|
Experimental: Part A: BI 764532 medium dose + carboplatin + etoposide
|
BI 764532
Standard of care
Standard of care
|
Experimental: Part A: BI 764532 high dose + carboplatin + etoposide
|
BI 764532
Standard of care
Standard of care
|
Experimental: Part B: BI 764532 + carboplatin + etoposide
|
BI 764532
Standard of care
Standard of care
|
Experimental: Part B: BI 764532 + cisplatin + etoposide
|
BI 764532
Standard of care
Standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part A: Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period
Time Frame: Up to 21 days.
|
Up to 21 days.
|
Part B: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment period
Time Frame: Up to 36 months.
|
Up to 36 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment period
Time Frame: Up to 36 months.
|
Up to 36 months.
|
|
Part A: Occurrence of adverse events (AEs) during the on-treatment period
Time Frame: Up to 36 months.
|
Up to 36 months.
|
|
Part B: Objective response (OR)
Time Frame: Up to 36 months.
|
Objective response (OR), defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 (based on investigator's assessment) from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.
|
Up to 36 months.
|
Part B: Duration of response (DoR)
Time Frame: Up to 36 months.
|
Duration of response (DoR), defined as the time from first documented confirmed objective response (OR) until the earliest date of disease progression or death among patients with confirmed objective response.
|
Up to 36 months.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Carboplatin
- Etoposide
Other Study ID Numbers
- 1438-0007
- U1111-1292-1400 (Registry Identifier: WHO Registry)
- 2023-505870-13-00 (Registry Identifier: CTIS (EU))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to:
https://www.mystudywindow.com/msw/datatransparency
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Neoplasms
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Roswell Park Cancer InstituteNot yet recruitingMalignant Solid Neoplasm | Lung Neuroendocrine Neoplasm | Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine NeoplasmUnited States
-
University of Roma La SapienzaRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1Italy
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Neuroendocrine Neoplasm | Metastatic Neuroendocrine Carcinoma | Metastatic Large Cell Neuroendocrine Carcinoma | Metastatic Small Cell Neuroendocrine CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Extrapulmonary Neuroendocrine Carcinoma | Metastatic Extrapulmonary Neuroendocrine Carcinoma | Recurrent Extrapulmonary Neuroendocrine Carcinoma | Unresectable Extrapulmonary Neuroendocrine CarcinomaUnited States
-
Fundación de investigación HMSyntax for Science, S.LRecruitingNeuroendocrine Tumours (NET) | Neuroendocrine Carcinomas (NEC)Spain
-
National Cancer Institute (NCI)RecruitingLocally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditionsUnited States
-
Roswell Park Cancer InstituteIpsenActive, not recruitingUnresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditionsUnited States
Clinical Trials on BI 764532
-
Boehringer IngelheimRecruitingNeuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)Netherlands
-
Boehringer IngelheimRecruitingPatients With Small Cell Lung Carcinoma and Other NeoplasmsUnited States, Spain, Germany, Japan
-
Boehringer IngelheimRecruitingSmall Cell Lung Carcinoma | Neuroendocrine NeoplasmsUnited States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, France, Portugal, Bulgaria
-
Boehringer IngelheimRecruitingNeuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)Germany, Belgium, Japan, France
-
Boehringer IngelheimRecruitingGliomaSpain, United States, Switzerland, Germany
-
Boehringer IngelheimRecruitingSmall Cell Lung Carcinoma (SCLC)United Kingdom, Germany, France, Poland
-
Boehringer IngelheimRecruitingSmall Cell Lung Carcinoma (SCLC)Spain, Belgium, Japan, France, Poland, Germany
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimNot yet recruiting
-
Boehringer IngelheimRecruitingMelanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)Netherlands